496 related articles for article (PubMed ID: 29563103)
1. Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.
Taraseviciute A; Tkachev V; Ponce R; Turtle CJ; Snyder JM; Liggitt HD; Myerson D; Gonzalez-Cuyar L; Baldessari A; English C; Yu A; Zheng H; Furlan SN; Hunt DJ; Hoglund V; Finney O; Brakke H; Blazar BR; Berger C; Riddell SR; Gardner R; Kean LS; Jensen MC
Cancer Discov; 2018 Jun; 8(6):750-763. PubMed ID: 29563103
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Santomasso BD; Park JH; Salloum D; Riviere I; Flynn J; Mead E; Halton E; Wang X; Senechal B; Purdon T; Cross JR; Liu H; Vachha B; Chen X; DeAngelis LM; Li D; Bernal Y; Gonen M; Wendel HG; Sadelain M; Brentjens RJ
Cancer Discov; 2018 Aug; 8(8):958-971. PubMed ID: 29880584
[TBL] [Abstract][Full Text] [Related]
3. Toxicities of CD19 CAR-T cell immunotherapy.
Hirayama AV; Turtle CJ
Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102
[TBL] [Abstract][Full Text] [Related]
4. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
5. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
6. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
7. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
8. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
Sterner RC; Sterner RM
Front Immunol; 2022; 13():879608. PubMed ID: 36081506
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis.
Wang N; Meng Y; Wu Y; He J; Liu F
Immunotherapy; 2021 Mar; 13(4):345-357. PubMed ID: 33406914
[No Abstract] [Full Text] [Related]
10. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
Gu T; Hu K; Si X; Hu Y; Huang H
WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
[TBL] [Abstract][Full Text] [Related]
11. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.
Gust J; Hay KA; Hanafi LA; Li D; Myerson D; Gonzalez-Cuyar LF; Yeung C; Liles WC; Wurfel M; Lopez JA; Chen J; Chung D; Harju-Baker S; Özpolat T; Fink KR; Riddell SR; Maloney DG; Turtle CJ
Cancer Discov; 2017 Dec; 7(12):1404-1419. PubMed ID: 29025771
[TBL] [Abstract][Full Text] [Related]
12. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
[No Abstract] [Full Text] [Related]
13. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
14. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
Chou CK; Turtle CJ
Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
[No Abstract] [Full Text] [Related]
15. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia.
Ma S; Wang Y; Qi K; Lu W; Qi Y; Cao J; Niu M; Li D; Sang W; Yan Z; Zhu F; Cheng H; Li Z; Zhao M; Xu K
Cancer Immunol Immunother; 2024 Apr; 73(6):104. PubMed ID: 38630258
[TBL] [Abstract][Full Text] [Related]
16. Cellular therapy: Immune-related complications.
Oved JH; Barrett DM; Teachey DT
Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities.
Dholaria BR; Bachmeier CA; Locke F
BioDrugs; 2019 Feb; 33(1):45-60. PubMed ID: 30560413
[TBL] [Abstract][Full Text] [Related]
18. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Hay KA; Hanafi LA; Li D; Gust J; Liles WC; Wurfel MM; López JA; Chen J; Chung D; Harju-Baker S; Cherian S; Chen X; Riddell SR; Maloney DG; Turtle CJ
Blood; 2017 Nov; 130(21):2295-2306. PubMed ID: 28924019
[TBL] [Abstract][Full Text] [Related]
19. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.
Rufener GA; Press OW; Olsen P; Lee SY; Jensen MC; Gopal AK; Pender B; Budde LE; Rossow JK; Green DJ; Maloney DG; Riddell SR; Till BG
Cancer Immunol Res; 2016 Jun; 4(6):509-19. PubMed ID: 27197068
[TBL] [Abstract][Full Text] [Related]
20. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Sterner RM; Sakemura R; Cox MJ; Yang N; Khadka RH; Forsman CL; Hansen MJ; Jin F; Ayasoufi K; Hefazi M; Schick KJ; Walters DK; Ahmed O; Chappell D; Sahmoud T; Durrant C; Nevala WK; Patnaik MM; Pease LR; Hedin KE; Kay NE; Johnson AJ; Kenderian SS
Blood; 2019 Feb; 133(7):697-709. PubMed ID: 30463995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]